Chapter 1 · The Number on the Screen

The exam room smelled like hand sanitizer and old magazines. Dr. Patel pulled up my labs on the screen and turned the monitor toward me. Most of the numbers meant nothing — a grid of abbreviations and decimal points that looked like someone else's homework. But one line was highlighted in red.

"Your ALT is 78," she said. "Normal is under 33."

I nodded like I understood. I did not understand.

The routine checkup that wasn't

I'd gone in for the usual: blood pressure, cholesterol, the annual wellness visit my insurance covered and my wife reminded me about every March. I'm 42, reasonably active, maybe fifteen pounds heavier than I'd like. I don't drink more than a beer or two on weekends. I thought my biggest health risk was the ergonomic disaster I call a desk chair.

Dr. Patel explained it calmly. ALT — alanine aminotransferase — is an enzyme that lives inside liver cells. When those cells are damaged, ALT leaks into the bloodstream. A reading of 78 meant something was irritating my liver. Not an emergency, she said. But not something to ignore.

"Have you heard of fatty liver disease?" she asked.

I hadn't. Not really. I vaguely associated liver problems with heavy drinking, and I told her so.

"That's a common misconception," she said. "Non-alcoholic fatty liver disease — NAFLD — is actually the most common liver condition in the world. About 38% of adults have some degree of it."

Thirty-eight percent. More than one in three. I sat with that number for a moment, trying to reconcile it with how invisible the condition seemed. Nobody I knew had ever mentioned it. No public health campaigns. No celebrity spokespeople. Just a quiet epidemic hiding in plain sight.

The ultrasound

Dr. Patel ordered an abdominal ultrasound. Two weeks later, I was lying on a table while a technician pressed a wand into my right side. The screen showed something that looked like a weather radar — gray blobs shifting as the wand moved.

The radiologist's report came back the next day: "Hepatic steatosis, grade 2." Three words that meant, in plain English, my liver had a moderate amount of excess fat.

I read the report twice, then a third time. Grade 2 out of 3. Not the worst, but not nothing. The fat wasn't supposed to be there, and if left unchecked, it could progress — from simple fat accumulation to inflammation (NASH), then to scarring (fibrosis), and eventually, in some cases, to cirrhosis or liver cancer.

That progression path scared me more than the diagnosis itself. Not because it was inevitable — Dr. Patel was clear that it wasn't — but because it was so quiet. Each stage could happen without symptoms. You wouldn't know you were getting worse until something very bad showed up on a blood test or a scan.

The Google spiral

That night, after the kids were asleep, I did what every newly diagnosed person does: I opened my laptop and fell into a search engine spiral.

The numbers were staggering. NAFLD affects an estimated 1.7 billion people worldwide. In the US alone, prevalence has climbed from about 25% to 38% in the last two decades. It's now the leading cause of chronic liver disease, surpassing hepatitis C and alcohol-related liver disease combined.

And yet most people with it don't know they have it. The condition is asymptomatic in its early stages. Liver enzymes might not even be elevated — Dr. Patel told me later that up to 50% of people with significant fatty liver have normal ALT levels. I was in the subset whose blood happened to tell the truth.

I learned that NAFLD had recently been renamed to MASLD — metabolic dysfunction-associated steatotic liver disease. The new name emphasized what the old one only hinted at: this isn't about alcohol. It's a metabolic condition, driven by insulin resistance, visceral fat, and the cascade of inflammation that follows.

The question

By midnight, my browser had thirty-seven tabs open. I'd read about FIB-4 scores (a fibrosis risk index I'd never heard of), about ALT thresholds, about the difference between a hepatologist and a gastroenterologist, about autophagy and ketosis and the Mediterranean diet.

I closed the laptop and stared at the ceiling. The information was overwhelming, but one thought cut through the noise: this is reversible. At my stage — grade 2 steatosis, no signs of fibrosis — the evidence was clear that lifestyle changes could meaningfully reduce hepatic fat. Not medication. Not surgery. Diet, fasting, movement.

The question wasn't whether it could be done. The question was whether I would actually do it.

I didn't have an answer yet. But I had a starting point: a number on a screen, a diagnosis I couldn't ignore, and the stubborn feeling that I owed my liver — and my family — a serious effort.

Dr. Patel had scheduled a follow-up in three months. Three months to learn, to change, to see if the numbers would move. That's where this story begins.